Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Additionally, it had been found that some patients with OCD symptoms had structural abnormalities in the brain
The FDA has warned consumers about dosing errors, questionable ingredients, and adverse events tied to some of these products
Nakamura BN, Lawson G, Chan JY, et al
The SURMOUNT-4 trial (NEJM, 2023) demonstrated that continued treatment is necessary to maintain weight loss, as participants who discontinued tirzepatide after achieving weight loss regained significant weight during the withdrawal phase
Demographics disparities in sex and race/ethnicity associated with weight-loss response were mirrored across both tirzepatide and semaglutide, suggesting that the observed distribution is not specific to a single agent
